Am J Obstet Gynecol

1. MAI PL, Miller A, Black A, Falk RT, et al
   Effect of Risk-Reducing Salpingo-Oophorectomy on Sex-Steroid Hormone Serum Levels among Post-Menopausal Women: An NRG Oncology/GOG Study.
   Am J Obstet Gynecol. 2022 Feb 22. pii: S0002-9378(22)00124.
   

   >> Share

   
   

   
   BMC Cancer

2. KENNEDY F, Shearsmith L, Holmes M, Rogers Z, et al
   Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study.
   BMC Cancer. 2022;22:726.
   

   >> Share

   
   

   
   Br J Cancer

3. NICHOLSON HA, Sawers L, Clarke RG, Hiom KJ, et al
   Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
   Br J Cancer. 2022 Jul 1. pii: 10.1038/s41416-022-01899.
   

   >> Share

   
   

   
   Clin Cancer Res

4. CHENG Z, Mirza H, Ennis DP, Smith P, et al
   The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
   Clin Cancer Res. 2022 Apr 10:OF1-OF12. doi: 10.1158/1078-0432.CCR-21-1643.
   

   >> Share

   
   

   
   Gynecol Oncol

5. WALL JA, Lipking K, Smith HJ, Huh WK, et al
   Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
   Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
   

   >> Share

   
   

   
   Hum Pathol

6. LONDERO AP, Orsaria M, Viola L, Marzinotto S, et al
   Survivin, Sonic hedgehog, Kruppel-like factors, and p53 pathway in serous ovarian cancer: an immunohistochemical study.
   Hum Pathol. 2022 Jun 28. pii: S0046-8177(22)00168.
   

   >> Share

   
   

   
   Int J Cancer

7. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
   The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
   Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
   

   >> Share

   
   

   
   Lancet Oncol

8. CLAMP AR, James EC, McNeish IA, Dean A, et al
   Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
   Lancet Oncol. 2022;23:919-930.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share